AUPH (Aurinia Pharmaceuticals Inc.) Stock Financials & Earnings

AUPHAurinia Pharmaceuticals Inc.

Mkt Cap$2B

Healthcare·Biotechnology·🇨🇦 Canada·NASDAQ

Revenue (TTM)$283M

Net Income (TTM)$287M

EPS (TTM)$2.07

Free Cash Flow (TTM)$134M

Gross Margin88.5%

Op. Margin37.1%

Net Margin101.5%

FCF Margin47.5%

P/S Ratio (TTM)6.9x

P/E Ratio (TTM)6.8x

YoY Rev Growth+20.4%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$34M	$34M	-$30M
Q2 23	$41M	$40M	-$16M
Q3 23	$55M	$48M	-$16M
Q4 23	$45M	$40M	-$30M
Q1 24	$50M	$43M	-$11M
Q2 24	$57M	$48M	-$2M
Q3 24	$68M	$62M	$12M
Q4 24	$60M	$54M	-$2M
Q1 25	$62M	$54M	$22M
Q2 25	$70M	$63M	$20M
Q3 25	$73M	$65M	$30M
Q4 25	$77M	$69M	$33M

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$13M	$50M	—	—
Q2 23	$13M	$44M	—	—
Q3 23	$14M	$48M	—	—
Q4 23	$10M	$50M	—	—
Q1 24	$6M	$45M	$3M	—
Q2 24	$4M	$41M	$4M	—
Q3 24	$3M	$40M	—	—
Q4 24	$8M	$31M	$14M	—
Q1 25	$6M	$19M	$970K	—
Q2 25	$7M	$25M	$848K	—
Q3 25	$8M	—	—	$26M
Q4 25	$11M	—	—	$29M

Revenue Segments

Quarter	License, Royalty and Collaboration Revenue	Product	License, Collaboration and Royalty Revenue
Q1 23	$72K	$34M	—
Q2 23	$394K	$41M	—
Q3 23	$14M	$41M	—
Q1 24	$2M	$48M	—
Q2 24	$2M	$55M	—
Q3 24	$12M	$56M	—
Q4 24	—	$58M	—
Q1 25	—	$60M	$2M
Q2 25	—	$67M	$3M
Q3 25	—	$71M	$3M
Q4 25	—	$74M	$3M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$89M	$273M	$362M
Q2 23	$82M	$269M	$351M
Q3 23	$46M	$292M	$338M
Q4 23	$49M	$302M	$350M
Q1 24	$64M	$255M	$320M
Q2 24	$33M	$297M	$330M
Q3 24	$37M	$312M	$349M
Q4 24	$83M	$275M	$358M
Q1 25	$66M	$246M	$313M
Q2 25	$53M	$262M	$315M
Q3 25	$73M	$279M	$352M
Q4 25	$80M	$318M	$398M

Shares Outstanding

Revenue Per Employee

Revenue / Employee